2016•BMJRequires access

Similar quit rates are found with three smoking cessation options

Jacqui Wise

Abstract

The drug varenicline (Champix) was found to be no better than combination nicotine replacement therapy or a standard nicotine patch in helping adults to stop smoking in the long term, a randomised controlled trial published in JAMA has shown.1 The researchers said that their open label study was the first to contrast varenicline and combination nicotine replacement therapies directly, both with one another and with the nicotine patch. Such a comparison …

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Varenicline, Nicotine replacement therapy, Smoking cessation, Medicine, Nicotine, Nicotine patch, Open label, Randomized controlled trial